Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD. John BV, Bastaich D, Singal AG, Dahman B, et al. Hepatology 2025 Oct 20. doi: 10.1097/HEP.0000000000001587.

Read + Share

Amedeo Smart

Independent Medical Education

John BV, Bastaich D, Singal AG, Dahman B, et al. Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD. Hepatology 2025 Oct 20. doi: 10.1097/HEP.0000000000001587.
PMID: 41115308